P. Falk

发表

Biochemical evidence for the formation of a covalent acyl-phosphate linkage between UDP-N-acetylmuramate and ATP in the Escherichia coli UDP-N-acetylmuramate:L-alanine ligase-catalyzed reaction.

H. T. Ho, K. M. Ervin, P. Falk, 1996, Biochemistry.

Structural studies of Escherichia coli UDP-N-acetylmuramate:L-alanine ligase.

H. T. Ho, R. Fairman, H. Jin, 1996, Biochemistry.

Comparison of the d-Glutamate-Adding Enzymes from Selected Gram-Positive and Gram-Negative Bacteria

M. Pucci, P. Falk, A. Walsh, 1999, Journal of bacteriology.

Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection.

A. Mathur, N. Meanwell, Chaoqun Chen, 2020, Journal of medicinal chemistry.

Steady-state kinetic mechanism of Escherichia coli UDP-N-acetylenolpyruvylglucosamine reductase.

H. T. Ho, J. Yanchunas, J. Villafranca, 1995, Biochemistry.

Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)

N. Meanwell, R. Colonno, Chaoqun Chen, 2012, Antimicrobial Agents and Chemotherapy.

Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

P. Falk, R. Rose, K. Ericson, 2018, Hepatology communications.

In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir

P. Falk, J. Friborg, F. Mcphee, 2014, Infectious Diseases and Therapy.

Scaffold modifications to the 4-(4,4-dimethylpiperidinyl) 2,6-dimethylpyridinyl class of HIV-1 allosteric integrase inhibitors.

K. Kish, N. Meanwell, M. Krystal, 2022, Bioorganic & medicinal chemistry.

Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.

K. Kish, N. Meanwell, C. Cianci, 2022, ACS medicinal chemistry letters.

Development of a Chimeric Replicon System for Phenotypic Analysis of Ns3 Protease Sequences from HCV Clinical Isolates

P. Falk, A. Sheaffer, J. Friborg, 2011, Antiviral therapy.

Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing.

L. Mueller, K. Kish, H. Klei, 2016, Journal of medicinal chemistry.

4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB.

H. T. Ho, M. Deshpande, W. Harte, 2000, Bioorganic & medicinal chemistry letters.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Discovery of the first antibacterial small molecule inhibitors of MurB.

M. Pucci, P. Falk, H. Ho, 2003, Bioorganic & medicinal chemistry letters.

The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection.

Qi Gao, Huabin Sun, Hong Shi, 2014, Journal of medicinal chemistry.

Resistance Analysis of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir

Chaoqun Chen, P. Falk, A. Sheaffer, 2012, Antimicrobial Agents and Chemotherapy.

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

T. Eley, P. Falk, R. Fridell, 2013, Hepatology.

Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.

P. Falk, F. Mcphee, P. Scola, 2013, Biochemical pharmacology.

UDP-N-acetylmuramyl-L-alanine functions as an activator in the regulation of the Escherichia coli glutamate racemase activity.

H. T. Ho, T. Dougherty, K. M. Ervin, 1995, Biochemistry.

Staphylococcus haemolyticus contains two D-glutamic acid biosynthetic activities, a glutamate racemase and a D-amino acid transaminase

H. T. Ho, T. Dougherty, M. Pucci, 1995, Journal of bacteriology.

P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor.

A. Good, N. Meanwell, R. Rajamani, 2018, Bioorganic & medicinal chemistry letters.

Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.

A. Good, K. Kish, H. Klei, 2018, ACS medicinal chemistry letters.

Development of an on-line automated sample clean-up method and liquid chromatography–tandem mass spectrometry analysis: application in an in vitro proteolytic assay

B. Warrack, Joseph L. Cantone, D. Drexler, 2006, Analytical and bioanalytical chemistry.

Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection.

A. Good, H. Klei, A. Cocuzza, 2014, Journal of medicinal chemistry.

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

T. Eley, P. Falk, R. Fridell, 2013, Hepatology.